Main Article Content
Abstract Diabetic nephropathy (DN) is one of the most common diabetic microvascular complication, which occurs in 20% to 40% of all patients with type 2 diabetes mellitus, is a metabolic disorder with high morbidity and mortality. The classical description of DN is a albumin in urine grows slowly and gradually. Myo-Inositol Oxygenase (MIOX) is regarded to be the most powerful organizer of Myo-inositol (MI) MI is mainly metabolized into D-glucuronic acid in the renal.
Objective To evaluate the role of early detection power of serum biomarkers irisin and MIOX for the diagnosis of type 2 diabetic patients with albuminuria.
Subjects and methods: a research implement within 160 entrant (illness and standard). The patient groups separated to: (40 T2DM.W.A), (40 T2DM.Mi) and (40 T2DM.Ma), (40 controls).This is a case control research. MIOX grads was measure by ELIZA, around 7ml of blood specimen were collected from patients and control. The excluded criteria of the study were patients Type1diabetes Mellitus, Recent type2 D.M. associated diseases with (heart failure, autoimmune disorders), No laboratory sign of hematuria or UTI, History of prolonged use of nephrotoxic drugs, Nephrotic range of proteinuria, End stage renal disease (ESRD), Patient's below 40 years old or older than 70 years old.
Result The patient groups with Type2 Diabetic Patients with Albuminuria present an eloquent rising in Serum MIOX grads in rapprochement to standard group (p < 0.001).
Conclusion A rise grade of Serum MIOX was diagnosed clinically who had Type2 Diabetic Patients with Albuminuria. Assay may be used as promoting biochemical markers for the early diagnosis and predicting of type 2diabetic patients with albuminuria.